Related Experiment Video
Updated: Apr 29, 2026
Non-invasive Optical Imaging of the Lymphatic Vasculature of a Mouse
Published on: March 8, 2013
Surveillance imaging for lymphoma: pros and cons
Ryan C Lynch1, Andrew D Zelenetz1, James O Armitage1
1From the: Division of Hospital Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO; Lymphoma Division, Memorial Sloan Kettering Cancer Center, New York, NY; Division of Oncology, Department of Medicine, University of Nebraska; Division of Oncology, Department of Medicine, Washington University School of Medicine; and Division of Hematology/Oncology, St. Louis VA Medical Center, St. Louis, MO.
There is no consensus on optimal lymphoma surveillance imaging frequency. While some guidelines suggest periodic scans, others find little benefit, citing risks and costs versus survival outcomes.
Area of Science:
- Oncology
- Radiology
- Medical Imaging
Background:
- Optimal surveillance imaging frequency and duration post-lymphoma treatment remain debated.
- Clinical practice guidelines offer conflicting recommendations on routine computed tomography (CT) or positron emission tomography (PET) scans.
- Lymphoma subtype influences theoretical surveillance needs, with aggressive types potentially requiring more frequent, shorter-term monitoring than indolent types.
Purpose of the Study:
- To present arguments for and against routine radiographic surveillance in lymphoma patients in remission.
- To facilitate understanding of the costs, risks, and benefits of surveillance imaging.
- To aid oncologists and patients in making informed clinical decisions regarding post-treatment follow-up.
Main Methods:
- Review of existing clinical practice guidelines and relevant studies on lymphoma surveillance.
- Discussion of theoretical considerations based on lymphoma subtypes and growth rates.
- Analysis of historical relapse detection methods versus current imaging capabilities.
Main Results:
- No definitive evidence shows improved overall survival by detecting relapse via imaging versus clinical symptoms.
- One study indicated a lower second-line International Prognostic Index (IPI) with imaging-detected relapse.
- Concerns exist regarding long-term risks of secondary malignancies from radiation exposure and significant costs of imaging.
Conclusions:
- The decision for surveillance imaging involves balancing potential benefits against risks (radiation exposure, secondary malignancies) and costs.
- Current evidence does not strongly support routine surveillance imaging for improved survival outcomes.
- Individualized clinical decisions between oncologists and patients are paramount.
